Depomed, Nautilus Neurosciences sales and marketing update

Depomed gained U.S. rights to Cambia diclofenac oral solution for migraines from Nautilus. Nautilus will receive $48.7 million in cash up front and will be eligible for up to $5 million in milestones on net sales. On a conference call to discuss the deal, Depomed said it immediately increased the price of Cambia by 26% "to close the gap versus other acute migraine products," such as Treximet sumatriptan/naproxen from Pozen Inc. (NASDAQ:POZN, Chapel Hill, N.C.) The previous wholesale acquisition cost (WAC) was $24.20 per dose. The company expects the move to increase annual sales of Cambia to about $22 million. ...